ABSTRACT:The objective of the present study was to evaluate the pattern of adverse drug reactions (ADRs) occurring in cancer patients treated with chemotherapy in tertiary care hospitals in Bangladesh. A prospective hospital based study over a period of six month was carried out in the Department of oncology, Bangabandhu Sheikh Mujib Medical University and Dhaka Medical College Hospital. The data were subjected to descriptive analysis. A total of 50 patients having ADRs due to cancer chemotherapy were randomly selected. Adverse drug reactions were mostly occurred in the age group between 41-50 years (26%). Considering socio-economic status of cancer patients married persons (82%) have significantly higher risk than unmarried (18%). Prevalence of breast cancer (20%), cervical cancer (14%) and leukemia (16%) were higher and they were treated mostly by adjuvant chemotherapy (46%) and secondly by chemotherapy (38%) alone. In most cases ADRs were developed in patients receiving alkylating agents (40%) and antimetabolites (40%) as anticancer therapy. The five certain ADRs observed in the current study were nausea, stomatitis, alopecia, myelosuppression and increased ESR level in both male and female patients. Moreover, hematological system was affected severely by alkylating agents and antimetabolites. Similar studies covering more patients from different regions are needed to validate our findings.

The funders had no role in study design, data collection and greater wall thickness, and higher prevalence of calcific atherosclerotic plaque in the degenerative group (all p<0.05). In multivariate analysis, congenital/genetically associated AA etiology conferred a 4-fold increment in magnitude of augmented native descending aortic strain after proximal grafting (B = 4.19 [CI 1.6, 6.8]; p = 0.002) independent of age and descending aortic size. Conclusions Prosthetic graft replacement of the ascending aorta increases magnitude and rapidity of distal aortic distension. Graft effects are greatest with congenital or genetically associated AA, providing a potential mechanism for increased energy transmission to the native descending aorta and adverse post-surgical aortic remodeling.

No abstract

BackgroundEchocardiography (echo) is widely used to guide therapeutic decision-making for patients being considered for MitraClip. Relative utility of two- (2D) and three-dimensional (3D) echo predictors of MitraClip response, and impact of MitraClip on mitral annular geometry, are uncertain.MethodsThe study population comprised patients with advanced (> moderate) MR undergoing MitraClip. Mitral annular geometry was quantified on pre-procedural 2D transthoracic echocardiography (TTE) and intra-procedural 3D transesophageal echocardiography (TEE); 3D TEE was used to measure MitraClip induced changes in annular geometry. Optimal MitraClip response was defined as ≤mild MR on follow-up (mean 2.7 ± 2.5 months) post-procedure TTE.ResultsEighty patients with advanced MR underwent MitraClip; 41% had optimal response (≤mild MR). Responders had smaller pre-procedural global left ventricular (LV) end-diastolic size and mitral annular diameter on 2D TTE (both p ≤ 0.01), paralleling smaller annular area and circumference on 3D TEE (both p = 0.001). Mitral annular size yielded good diagnostic performance for optimal MitraClip response (AUC 0.72, p < 0.01). In multivariate analysis, sub-optimal MitraClip response was independently associated with larger pre-procedural mitral annular area on 3D TEE (OR 1.93 per cm2/m2 [CI 1.19–3.13], p = 0.007) and global LV end-diastolic volume on 2D TTE (OR 1.29 per 10 ml/m2 [CI 1.02–1.63], p = 0.03). Substitution of 2D TTE derived mitral annular diameter for 3D TEE data demonstrated a lesser association between pre-procedural annular size (OR 5.36 per cm/m2 [CI 0.95–30.19], p = 0.06) and sub-optimal MitraClip response. Matched pre- and post-procedural TEE analyses demonstrated MitraClip to acutely decrease mitral annular area and circumference (all p < 0.001) as well as mitral tenting height, area, and volume (all p < 0.05): Magnitude of MitraClip induced reductions in mitral annular circumference on intra-procedural 3D TEE was greater among patients with, compared to those without, sub-optimal MitraClip response (>mild MR) on followup TTE (p = 0.017); greater magnitude of device-induced annular reduction remained associated with sub-optimal MitraClip response even when normalized for pre-procedure annular circumference (p = 0.028).ConclusionsMitraClip alters mitral annular geometry as quantified by intra-procedural 3D TEE. Pre-procedural mitral annular dilation and magnitude of device-induced reduction in mitral annular size on 3D TEE are each associated with sub-optimal therapeutic response to MitraClip.

No abstract